Emerging molecular targeted therapies in the treatment of head and neck cancer

Bibliography

• Ragin CC, Modugno F, Gollin SM. The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res 2007;86(2):104-14
   PubMed Web of Science ®Google Scholar
• Dassonville O, Bozec A, Fischel JL, Milano G. EGFR-targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. Crit Rev Oncol Hematol 2007;62(1):53-61
   PubMed Web of Science ®Google Scholar
• Dassonville O, Formento JL, Francoual M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993;11(10):1873-8
   PubMed Web of Science ®Google Scholar
• Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23(11):2445-59
   PubMed Web of Science ®Google Scholar
• Bozec A, Poissonnet G, Chamorey E, et al. Free-flap head and neck reconstruction and quality of life: a 2-year prospective study. Laryngoscope 2008;118(5):874-80
   PubMed Web of Science ®Google Scholar
• Harari PM. Promising new advances in head and neck radiotherapy. Ann Oncol 2005;16(Suppl 6):vi13-9
   PubMed Web of Science ®Google Scholar
• Pignon JP, le Maitre A, Bourhis J. Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 2007;69(2 Suppl):S112-4
   PubMed Web of Science ®Google Scholar
• Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357(17):1705-15
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357(17):1695-704
   PubMed Web of Science ®Google Scholar
• Poissonnet G, Benezery K, Peyrade F, et al. Upper aerodigestive tract carcinoma: therapeutic management. Presse Med 2007;36(11 Pt 2):1634-42
   PubMed Web of Science ®Google Scholar
• Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008;371(9625):1695-709
   PubMed Web of Science ®Google Scholar
• Gold KA, Lee HY, Kim ES. Targeted therapies in squamous cell carcinoma of the head and neck. Cancer 2009;115(5):922-35
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567-78
   PubMed Web of Science ®Google Scholar
• Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23(24):5578-87
   PubMed Web of Science ®Google Scholar
• Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23(24):5568-77
   PubMed Web of Science ®Google Scholar
• Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23(34):8646-54
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116-27
   PubMed Web of Science ®Google Scholar
• Merck Annual Report 2007. Merck Serono – Markets – Oncology 2007. Available from: www.reports.merck.de/2007/ar/managementreportdivisions/merckserono/markets/oncology.html
   Google Scholar
• Erbitux will reach US$ 250 million in sales in 2015, a five-fold increase in the value of the entire 2005 head and neck cancer drug market. Press Releases 2006. Available from: www.pharmalicensing.com/public/press/view/1163428872_45588408ed4af/erbitux-will-reach-us-250-million-in-sales-in-2015-a-five-fold-increase-in-the-value-of-the-entire-2005-head-and-neck-cancer-drug-market
   Google Scholar
• Wang LX, Agulnik M. Promising newer molecular-targeted therapies in head and neck cancer. Drugs 2008;68(12):1609-19
   PubMed Web of Science ®Google Scholar
• Molinolo AA, Amornphimoltham P, Squarize CH, et al. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 2008; In press, doi:10.1016/j.oraloncology.2008.07.011
   PubMed Web of Science ®Google Scholar
• Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53(15):3579-84
   PubMed Web of Science ®Google Scholar
• Ciardiello F. Epidermal growth factor receptor inhibitors in cancer treatment. Future Oncol 2005;1(2):221-34
   PubMedGoogle Scholar
• Iwase M, Takaoka S, Uchida M, et al. Epidermal growth factor receptor inhibitors enhance susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells. Oral Oncol 2008;44(4):361-8
   PubMed Web of Science ®Google Scholar
• Bozec A, Formento P, Ciccolini J, et al. Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation. Mol Cancer Ther 2005;4(12):1962-71
   PubMed Web of Science ®Google Scholar
• Hirata A, Ogawa S, Kometani T, et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002;62(9):2554-60
   PubMed Web of Science ®Google Scholar
• Taylor RJ, Chan SL, Wood A, et al. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2008; In press, doi:10.1007/s00262-008-0613-3
   Google Scholar
• Mellstedt H. Monoclonal antibodies in human cancer. Drugs Today (Barc) 2003;39(Suppl C):1-16
   PubMed Web of Science ®Google Scholar
• Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001;1(2):118-29
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23(5):1011-27
   PubMed Web of Science ®Google Scholar
• Bock JM, Sinclair LL, Bedford NS, et al. Modulation of cellular invasion by VEGF-C expression in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2008;134(4):355-62
   PubMed Web of Science ®Google Scholar
• Siemann DW, Bibby MC, Dark GG, et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005;11(2 Pt 1):416-20
   PubMed Web of Science ®Google Scholar
• Bozec A, Gros FX, Penault-Llorca F, et al. Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition. Eur J Cancer 2008;44(13):1922-30
   PubMed Web of Science ®Google Scholar
• Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10(2):415-27
   PubMed Web of Science ®Google Scholar
• Bozec A, Lassalle S, Gugenheim J, et al. Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126. Br J Cancer 2006;95(6):722-8
   PubMed Web of Science ®Google Scholar
• Bianco C, Tortora G, Bianco R, et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002;8(10):3250-8
   PubMed Web of Science ®Google Scholar
• Magne N, Fischel JL, Dubreuil A, et al. Sequence-dependent effects of ZD1839 (‘Iressa’) in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 2002;86(5):819-27
   PubMed Web of Science ®Google Scholar
• Hagan M, Yacoub A, Dent P. Ionizing radiation causes a dose-dependent release of transforming growth factor alpha in vitro from irradiated xenografts and during palliative treatment of hormone-refractory prostate carcinoma. Clin Cancer Res 2004;10(17):5724-31
   PubMed Web of Science ®Google Scholar
• Bozec A, Thariat J, Bensadoun RJ, Milano G. Chemoradiotherapy in head and neck squamous cell carcinoma: focus on targeted therapies. Cancer Radiother 2008;12(1):14-24
   PubMed Web of Science ®Google Scholar
• Cao C, Albert JM, Geng L, et al. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer. Cancer Res 2006;66(23):11409-15
   PubMed Web of Science ®Google Scholar
• Bozec A, Sudaka A, Fischel JL, et al. Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model. Br J Cancer 2008;99(1):93-9
   PubMed Web of Science ®Google Scholar
• Bozec A, Formento P, Lassalle S, et al. Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts. Br J Cancer 2007;97(1):65-72
   PubMed Web of Science ®Google Scholar
• Ning S, Laird D, Cherrington JM, Knox SJ. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res 2002;157(1):45-51
   PubMed Web of Science ®Google Scholar
• Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002;53(1):164-71
   PubMed Web of Science ®Google Scholar
• Wachsberger PR, Burd R, Marero N, et al. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 2005;11(2 Pt 1):835-42
   PubMed Web of Science ®Google Scholar
• Kondo N, Ishiguro Y, Kimura M, et al. Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab. Oncol Rep 2008;20(2):373-8
   PubMed Web of Science ®Google Scholar
• Montemurro F, Valabrega G, Aglietta M. Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin Biol Ther 2007;7(2):257-68
   PubMed Web of Science ®Google Scholar
• Herbst RS, Heymach JV, O'Reilly MS, et al. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 2007;16(2):239-49
   PubMed Web of Science ®Google Scholar
• Sano D, Kawakami M, Fujita K, et al. Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. Oncol Rep 2007;17(2):289-95
   PubMed Web of Science ®Google Scholar
• Gustafson DL, Frederick B, Merz AL, Raben D. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. Cancer Chemother Pharmacol 2008;61(2):179-88
   PubMed Web of Science ®Google Scholar
• Zhang Q, Thomas SM, Xi S, et al. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 2004;64(17):6166-73
   PubMed Web of Science ®Google Scholar
• Koppikar P, Choi SH, Egloff AM, et al. Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res 2008;14(13):4284-91
   PubMed Web of Science ®Google Scholar
• Kijima T, Niwa H, Steinman RA, et al. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ 2002;13(8):355-62
   PubMedGoogle Scholar
• Boehm AL, Sen M, Seethala R, et al. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck. Mol Pharmacol 2008;73(6):1632-42
   PubMed Web of Science ®Google Scholar
• Amornphimoltham P, Patel V, Leelahavanichkul K, et al. A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer. Cancer Res 2008;68(4):1144-53
   PubMed Web of Science ®Google Scholar
• Aissat N, Le Tourneau C, Ghoul A, et al. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 2008;62(2):305-13
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Siu LL. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. Curr Opin Oncol 2008;20(3):256-63
   PubMed Web of Science ®Google Scholar
• Barnes CJ, Ohshiro K, Rayala SK, et al. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 2007;13(14):4291-9
   PubMed Web of Science ®Google Scholar
• Bonner JA. Prolongation of survival with the addition of cetuximab to radiation in patients with locoregionally advanced head and neck cancer (SCCHN): five-year results from a randomized trial. Presented at: American Society for Therapeutic Radiology and Oncology's 50th Annual Meeting, Boston, 2008 September 21-25
   Google Scholar
• Bernier J, Bonner J, Vermorken JB, et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008;19(1):142-9
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Chen EX. Molecularly targeted agents in the treatment of recurrent or metastatic squamous cell carcinomas of the head and neck. Hematol Oncol Clin North Am 2008;22(6):1209-20, ix
   PubMed Web of Science ®Google Scholar
• Langer CJ. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer 2008;112(12):2635-45
   PubMed Web of Science ®Google Scholar
• Lopez-Albaitero A, Ferris RL. Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg 2007;133(12):1277-81
   PubMed Web of Science ®Google Scholar
• Kruser TJ, Armstrong EA, Ghia AJ, et al. Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer. Int J Radiat Oncol Biol Phys 2008;72(2):534-42
   PubMed Web of Science ®Google Scholar
• Dietz A, Boehm A, Mozet C, et al. Current aspects of targeted therapy in head and neck tumors. Eur Arch Otorhinolaryngol 2008;265(Suppl 1):S3-12
   PubMed Web of Science ®Google Scholar
• Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20(21):4292-302
   PubMed Web of Science ®Google Scholar
• Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22(1):77-85
   PubMed Web of Science ®Google Scholar
• Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21(10):1980-7
   PubMed Web of Science ®Google Scholar
• Belon J, Irigoyen A, Rodriguez I, et al. Preliminary results of a phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck [abstract 5563]. J Clin Oncol 2005;23(Suppl)
   PubMed Web of Science ®Google Scholar
• Kim ES, Kies M, Glisson BS, et al. Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent / metastatic head and neck cancer [abstract 6013]. J Clin Oncol 2007;25(Suppl)
   Google Scholar
• Wirth LJ, Haddad RI, Lindeman NI, et al. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23(28):6976-81
   PubMed Web of Science ®Google Scholar
• Abidoye OO, Cohen EE, Wong SJ, et al. A phase II study of lapatinib (GW572016) in recurrent / metastatic squamous cell carcinoma of the head and neck [abstract 5568]. J Clin Oncol 2006;24(Suppl)
   Google Scholar
• Available from: www.clinicaltrials.gov
   Google Scholar
• Cooney MM, Tserng KY, Makar V, et al. A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck. Cancer Chemother Pharmacol 2005;55(3):295-300
   PubMed Web of Science ®Google Scholar
• Elser C, Siu LL, Winquist E, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007;25(24):3766-73
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Haraf DJ, Cohen EE, et al. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol 2008;26(10):1732-41
   PubMed Web of Science ®Google Scholar
• Cohen EE, Davis DW, Karrison TG, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009;10(3):247-57
   PubMed Web of Science ®Google Scholar
• Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006;24(7):1072-8
   PubMed Web of Science ®Google Scholar
• Suntharalingam M, Taylor R, Wolf J. Initial report of phase II trial of weekly cetuximab, CBDCA, paclitaxel and daily radiotherapy in patients with locally advanced SCCHN. Presented at: Multidisciplinary head and neck cancer symposium, California, 2007 January 18-20
   Google Scholar
• Zhang Y, Ma QY, Dang CX, et al. Quantitative molecular diagnosis of axillary drainage fluid for prediction of locoregional failure in patients with one to three positive axillary nodes after mastectomy without adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2006;64(2):505-11
   PubMed Web of Science ®Google Scholar
• Decker D, Tolba R, Springer W, et al. Abdominal surgical interventions: local and systemic consequences for the immune system–a prospective study on elective gastrointestinal surgery. J Surg Res 2005;126(1):12-8
   PubMed Web of Science ®Google Scholar
• Guller U, Zajac P, Schnider A, et al. Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg 2002;236(6):768-75; discussion 775-6
   PubMed Web of Science ®Google Scholar
• Delord J, Thomas A, Benlyazid J, et al. Neo-adjuvant treatment with erlotinib in squamous cell carcinoma head and neck (SCCHN) patients before surgery provides an opportunity to find predictive factors of response [abstract 5513]. J Clin Oncol 2006;18(Suppl)
   Google Scholar
• Grandis JR, Lai SY, Esteve FR, et al. Erlotinib (E) as adjuvant treatment for patients (pts) with resected head and neck squamous cell carcinoma (HNSCC) with evaluation of neoadjuvant biomarker modulation with E with or without sulindac (S): a feasibility report [abstract 6037]. J Clin Oncol 2008;20(Suppl)
   Google Scholar
• Savvides P, Greskovich J, Bokar JA, et al. Phase II study of bevacizumab with docetaxel and radiation in locally advanced head and neck squamous cell cancer [abstract 6071]. J Clin Oncol 2008;20(Suppl)
   Google Scholar
• Kies MS, Gibson MK, Kim SW, et al. Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN): an interim analysis [abstract 6072]. J Clin Oncol 2008;20(Suppl)
   Google Scholar
• Forastiere AA, Burtness BA. Epidermal growth factor receptor inhibition in head and neck cancer–more insights, but more questions. J Clin Oncol 2007;25(16):2152-5
   PubMed Web of Science ®Google Scholar
• Temam S, Kawaguchi H, El-Naggar AK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007;25(16):2164-70
   PubMed Web of Science ®Google Scholar
• Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006;24(25):4170-6
   PubMed Web of Science ®Google Scholar
• Willmore-Payne C, Holden JA, Layfield LJ. Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck. Mod Pathol 2006;19(5):634-40
   PubMed Web of Science ®Google Scholar
• Huang HS, Nagane M, Klingbeil CK, et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 1997;272(5):2927-35
   PubMed Web of Science ®Google Scholar
• Wikstrand CJ, Hale LP, Batra SK, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995;55(14):3140-8
   PubMed Web of Science ®Google Scholar
• Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 1997;57(18):4130-40
   PubMed Web of Science ®Google Scholar
• Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006;12(17):5064-73
   PubMed Web of Science ®Google Scholar
• Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66(8):3992-5
   PubMed Web of Science ®Google Scholar
• Ichikawa T, Yano Y, Uchida M, et al. The activation of K-ras gene at an early stage of lung tumorigenesis in mice. Cancer Lett 1996;107(2):165-70
   PubMed Web of Science ®Google Scholar
• Yamashita N, Minamoto T, Ochiai A, et al. Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon. Gastroenterology 1995;108(2):434-40
   PubMed Web of Science ®Google Scholar
• Yarbrough WG, Shores C, Witsell DL, et al. ras mutations and expression in head and neck squamous cell carcinomas. Laryngoscope 1994;104(11 Pt 1):1337-47
   PubMed Web of Science ®Google Scholar
• Matsuda H, Konishi N, Hiasa Y, et al. Alterations of p16/CDKN2, p53 and ras genes in oral squamous cell carcinomas and premalignant lesions. J Oral Pathol Med 1996;25(5):232-8
   PubMed Web of Science ®Google Scholar
• Saranath D, Chang SE, Bhoite LT, et al. High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India. Br J Cancer 1991;63(4):573-8
   PubMed Web of Science ®Google Scholar
• Spencer JM, Kahn SM, Jiang W, et al. Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinomas. Arch Dermatol 1995;131(7):796-800
   PubMed Web of Science ®Google Scholar
• McDonald JS, Jones H, Pavelic ZP, et al. Immunohistochemical detection of the H-ras, K-ras, and N-ras oncogenes in squamous cell carcinoma of the head and neck. J Oral Pathol Med 1994;23(8):342-6
   PubMed Web of Science ®Google Scholar
• Hoa M, Davis SL, Ames SJ, Spanjaard RA. Amplification of wild-type K-ras promotes growth of head and neck squamous cell carcinoma. Cancer Res 2002;62(24):7154-6
   PubMed Web of Science ®Google Scholar
• Atkinson DM, Clarke MJ, Mladek AC, et al. Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts. Head Neck 2008;30(6):790-9
   PubMed Web of Science ®Google Scholar
• Penault-Llorca F, Bibeau F, Arnould L, et al. EGFR expression in colorectal cancer and role in tumorigenesis. Bull Cancer 2005;92(Spec no):S5-11
   PubMed Web of Science ®Google Scholar
• Agulnik M, da Cunha Santos G, Hedley D, et al. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol 2007;25(16):2184-90
   PubMed Web of Science ®Google Scholar
• Calvo E, Malik SN, Siu LL, et al. Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer. Ann Oncol 2007;18(4):761-7
   PubMed Web of Science ®Google Scholar